The development of more specific ligands of PPARγ, namely the thiazolidinedione (TZD) class of oral antidiabetics has prompted experimental studies to further validate PPARγ-mediated neuroprotection in models of cerebral ischemia, Parkinson’s disease (PD), amyotrophic lateral sclerosis, and AD [10]. The gene discussed is PPARG; the disease is brain ischemia.